Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA; Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
Indian J Ophthalmol. 2019 Dec;67(12):2071-2073. doi: 10.4103/ijo.IJO_663_19.
A 60-year-old Caucasian female was referred for biopsy-proven amelanotic orbito-conjunctival melanoma. Map biopsies revealed residual invasive melanoma on the deep tarsal margin at the site of previous surgery. Repeat excisions were required after recurrence was detected following 3 months and 7 months. Positron emission tomography scan detected liver metastasis and additional orbito-conjunctival melanoma recurrence. Biomarker testing showed NRAS mutation without BRAF or c-KIT mutations and without PD-L1 expression. Systemic checkpoint inhibitor therapy was initiated with regression of both the orbito-conjunctival melanoma and liver metastasis. Invasive, non resectable orbito-conjunctival melanoma with liver metastasis can demonstrate a response to systemic checkpoint inhibitor therapy.
一位 60 岁的白种女性患者因活检证实的无黑色素眼窝结膜黑色素瘤而被转介。地图活检显示,在先前手术部位的深层睑板缘处仍有侵袭性黑色素瘤。复发后 3 个月和 7 个月后需要再次进行切除。正电子发射断层扫描显示肝转移和其他眼窝结膜黑色素瘤复发。生物标志物检测显示NRAS 突变,无 BRAF 或 c-KIT 突变,也无 PD-L1 表达。开始全身检查点抑制剂治疗后,眼窝结膜黑色素瘤和肝转移均有消退。侵袭性、不可切除的眼窝结膜黑色素瘤伴肝转移可对全身检查点抑制剂治疗产生反应。